Stock screenerAll disclosures →
EDGAR →
ORKA
Conviction 61HealthcareScan · Thu, Sep 24, 2026Oruka Therapeutics, Inc. (ORKA) closed at $85.53 (-4.89%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 37, RS Rating 99, -24.4% from its 52-week high, +202.6% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
ORKA$85.53-4.89%
ResistanceSupportVol 14Insider sell5
9
4
4
6
5
Vol MA14 1.1M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price85.53
Change-4.89%
Gap-1.56%
Rel volume2.82×
Avg volume992.89K
Avg $ vol91.57M
SMA 2092.76
SMA 5096.65
SMA 20062.33
Price vs 50-11.50%
Price vs 200+37.21%
MA stackmixed
50/200 cross—
Supertrenddown · 102.45
RSI (14)37
MACD hist-0.60
MACD crossbear · 1d
Stoch %K / %D18 / 40
ADX (14)17
+DI / −DI14 / 26
RSI divergence—
MACD divergence—
ATR %6.41%
ADR %5.47%
52w high113.08
52w low15.05
From 52w high-24.36%
Above 52w low+468.31%
New 52w highNo
SqueezeOn · 3d
Bollinger width11.06%
%B-0.20
Donchian pos16.43%
Donchian high99.62
Donchian low82.76
AVWAP (52w high)95.28
vs AVWAP high-10.23%
AVWAP (52w low)64.62
vs AVWAP low+32.36%
OBV trendDown
Chaikin MF (20)-0.06
Today vs 20d2.82×
Avg vol (14d)1.1M
Avg vol (20d)992.89K
Avg $ vol (20d)91.57M
Market cap5.66B
RS Rating99 / 99
RS 3m (vs SPY)-5.76%
RS 6m (vs SPY)+78.41%
RS line new highNo
Trend template6/8
Technical rank64.2
1 week-12.48%
1 month-16.00%
3 months-1.27%
6 months+95.23%
1 year+449.68%
YTD+202.55%
P/E-53.71
P/B5.08
P/S—
P/FCF-64.05
EPS-3.87
Div yield—
ROE-9.46%
ROA-9.25%
Debt/Eq—
Current38.51
EV/EBITDA-44.21
Gross margin—
Net margin—
Rev growth—
EPS growth-25.93%
Price target154.09
Target upside80.16%
Analyst ratingBuy
Institutional115.68%
Ent. value5.39B
Revenue0
Net income-41.21M
Gross profit—
Free cash flow-88.42M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out60.31M
Employees68
ListedTue, Sep 3, 2024
Free float35.3M
Float %72.9%
Short interest7.79M
Days to cover9.3d
Short volume50.4%
Squeeze score87 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.55 vs −$0.49
Last surprise-12.2% miss
Setup gradeB
Conviction61 / 100
Pattern quality—
Tech rank64.2 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance106.90
Support86.84
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For ShareholdersYahoo Finance · Thu, Sep 24, 2026
- Oruka Therapeutics Says Psoriasis Drug Shows Deepening EfficacyYahoo Finance · Wed, Sep 23, 2026
- Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial DataAdvfn · Wed, Sep 23, 2026
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional DosingYahoo Finance · Wed, Sep 23, 2026
Congress activity
Disclosed STOCK Act trades in ORKA
No recent disclosed trades by Congress in ORKA. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ORKA · open-market 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Agarwal Arjun Senior Vice President, Finance · Common Stock · 2026-09-21 | Sell | 533 | $51K | 2026-09-21 | 2026-09-21 |
Quinlan Paul T General Counsel · Common Stock · 2026-09-21 | Exercise | 10K | $78K | 2026-09-21 | 2026-09-21 |
Quinlan Paul T General Counsel · Common Stock · 2026-09-21 | Sell | 2.9K | $268K | 2026-09-21 | 2026-09-21 |
Quinlan Paul T General Counsel · Common Stock · 2026-09-21 | Sell | 3.83K | $358K | 2026-09-21 | 2026-09-21 |
Quinlan Paul T General Counsel · Common Stock · 2026-09-21 | Sell | 601 | $57K | 2026-09-21 | 2026-09-21 |
Quinlan Paul T General Counsel · Common Stock · 2026-09-21 | Sell | 2.67K | $254K | 2026-09-21 | 2026-09-21 |
Quinlan Paul T General Counsel · Employee Warrant (right to buy) · 2026-09-21 | Exercise | 10K | — | 2026-09-21 | 2026-09-21 |
Goncalves Joana Chief Medical Officer · Common Stock · 2026-09-15 | Sell | 1.37K | $127K | 2026-09-15 | 2026-09-15 |
Agarwal Arjun Senior Vice President, Finance · Common Stock · 2026-09-15 | Sell | 560 | $54K | 2026-09-15 | 2026-09-15 |
Goncalves Joana Chief Medical Officer · Common Stock · 2026-09-15 | Exercise | 3.5K | $24K | 2026-09-15 | 2026-09-15 |
SEC filings
EDGAR filings in ORKA · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.